MedTrace Logo

A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)

NCT05052892 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-04-25

No results posted yet for this study

Summary

Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis. However, the practice of HVPG is limited to require the extensive experience and highly specialized centers. In recent years, non-invasive methods were proposed to predict the degree of cirrhotic portal hypertension. Of them, liver stiffness measured by FibroScan had shown good performance for predicting clinically significant portal hypertension. However, the correlation between liver stiffness and HVPG was poor when HVPG was more than 12mmHg. Since the spleen was stiffer than the liver, the current vibration-controlled transient elastography examination is dedicated to the liver, rather than the spleen. Very recently, a novel spleen-dedicated stiffness measured by FibroScan was proposed. The prospective, multicenter study aims to evaluate the correlation between SS (measured by the novel FibroScan) and HVPG, and further develop a novel model based on SS for predicting the liver decompensation in patients with compenstaed cirrhosis.

Conditions

  • Portal Hypertension

Interventions

DIAGNOSTIC_TEST

Hepatic venous pressure gradient

All patients underwent measurement of HVPG under local anesthesia.

Sponsors & Collaborators

  • LanZhou University

    collaborator OTHER

  • Shulan (Hangzhou) Hospital

    collaborator OTHER

  • The Third People's Hospital of Taiyuan

    collaborator OTHER

  • Hepatopancreatobiliary Surgery Institute of Gansu Province

    lead OTHER

Principal Investigators

  • Lanjuan Li, MD · Shulan (Hangzhou) Hospital

  • Xiaolong Qi, MD · LanZhou University

  • Huadong Yan, MD · Shulan (Hangzhou) Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-28
Primary Completion
2025-09-27
Completion
2025-09-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052892 on ClinicalTrials.gov